Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. AAPL
6. MRVL
7. CL
8. TFII
9. LYB
10. RXRX

Go back to Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

Argos Therapeutics (ARGS) Announces Update on Immunology Data from the Phase 3 ADAPT Trial

November 13, 2017 5:46 AM EST

Argos Therapeutics, Inc. (NASDAQ: ARGS) today provided an update on the immunology data from the February 2017 interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma (mRCC) presented in the poster session at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland. The presentation is focused primarily... More